
zzso is a highly prevalent condition in cancer patients zzso on zzso mortality and quality of zzso zzso zzso zzso 500 zzso administered once every 3 weeks zzso has been shown to be effective in patients with zzso zzso 

This zzso study investigated the efficacy and usage patterns of zzso 500 zzso zzso in routine clinical zzso 

Prospective data on adult zzso cancer patients receiving zzso zzso zzso during chemotherapy was zzso zzso of zzso treatment was measured as the red blood cell zzso zzso zzso the change in zzso over time, zzso for zzso and the change in Eastern Cooperative Oncology Group zzso performance status between baseline and study zzso zzso patterns were evaluated in zzso categories at baseline and week 16, zzso dosage information, and adherence to the guidelines issued by the European zzso for Research and Treatment of Cancer zzso 

A total of 309 patients were zzso The median study duration was 16 weeks and the overall zzso rate was zzso zzso fewer patients required zzso when zzso was initiated at zzso zzso zzso zzso as compared to later at a zzso zzso zzso zzso zzso p zzso zzso zzso patients had fewer zzso zzso and better zzso scores at the end of the zzso A total of zzso of patients reached a zzso zzso zzso zzso during weeks zzso zzso adherence to zzso thresholds for zzso initiation as recommended by the zzso was observed in zzso of zzso 

In accordance with the recommended treatment objective for zzso to zzso zzso zzso of study patients remained free of zzso during zzso 500 zzso zzso treatment and at an even higher rate if zzso treatment was initiated before zzso fell below zzso zzso 

